CAPS and cystadenoma: Interestingly, the average percentage of CAPS+ cells for all cases decreased with increasing grade aggressiveness of serous lesions (~40% in cystadenomas, ~30% in borderline tumors, ~20% in low-grade carcinomas, and <3% in HGSOCs.